Johnson & Johnson (JNJ)
J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
A Johnson & Johnson subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant seeks to advance an approximately $8 billion proposed settlement that would end tens of thousands of lawsuits alleging that the company's baby powder and other talc products caused cancer.
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Pick Disney Over Johnson & Johnson Stock
Given its attractive valuation, we believe that Disney stock (NYSE: DIS) is currently a better pick than the pharmaceuticals bellwether – Johnson & Johnson stock (NYSE: JNJ). The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.
J&J gets $260 mln talc verdict overturned in Oregon, new trial ordered
An Oregon judge has overturned a $260 million verdict against Johnson & Johnson in a lawsuit brought by a woman who said she got mesothelioma, a deadly cancer linked to asbestos exposure, from inhaling the company's talc powder, the company said on Monday.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
How To Earn $500 A Month From Johnson & Johnson Stock
On Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.
US FDA expands J&J's psoriasis drug for inflammatory bowel disease
The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesday.
3 Safe Stocks with Safe Dividends for Your Portfolio
The stock market can feel like a roller coaster, especially during economic uncertainty. As fears of a recession increase, investors seek stability and look for investments that can weather the storm and offer a sense of security.
Top 3 recession-proof stocks to buy as US monthly jobs data disappoints again
The US nonfarm payrolls grew sharply on a month-over-month basis in August but still came in below the consensus forecast on Friday. The US economy added 142,000 jobs last month versus 89,000 in July and 161,000 that the Dow Jones estimate had called for.
Johnson & Johnson (JNJ) Wells Fargo 2024 Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica Moore - Vice President of Investor Relations Tracy Menkowski - Senior Director of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Barry, we're ready? All right, good morning.
